This provides evidence that targeting the CD44v6-WNT3A mediated β-catenin/TCF4-MDR1 signaling pathways and the increased MDR1 efflux function may represent a novel approach to overcome chemotherapy resistance in colon tumor CICs. The gene discussed is WNT3A; the disease is colonic neoplasm.